Acta Pharmacologica Sinica - CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats Skip to main content Thank you for visiting nature.com.

The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding concomitant use of strong and moderate CYP3A4 inhibitors or inducers.

CYP3A4 inducers, including: • rifampin (Rimactane) • phenytoin (Dilantin) • carbamazepine (Tegretol, others) The CYP3A4 enzyme helps break down Ubrelvy after you take a dose.

May 12, 2004 — Substantial increases in trazodone hydrochloride (Desyrel) plasma concentration may occur with concurrent dosing of the cytochrome P450 3A4 (CYP3A4) inhibitors ketoconazole ...

CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19. Concomitant use with CYP3A4, CYP2C19, or CYP2C9 substrates may reduce plasma concentration of these drugs.

Concomitant strong CYP3A4 inducers (eg, phenytoin, carbamazepine, St. Johns wort, rifampin): not recommended; may need to increase clozapine dose. Concomitant weak or moderate CYP1A2 ...